📖
Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis.
Haiya F, Qianqian L, Yangjun L, Hui W

Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis.

Author / Organization:
Medicine & Health Published 2026 Verification Pending

Overview & Synopsis

Open access biomedical research article published in J Cancer Res Clin Oncol.

Indexed from repository: PubMed Central (pmc.ncbi.nlm.nih.gov)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis.
Author / Organization Haiya F, Qianqian L, Yangjun L, Hui W
Subject & Discipline J Cancer Res Clin Oncol
Categories Medicine & Health
Publication Year 2026
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website PubMed Central (pmc.ncbi.nlm.nih.gov)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-137342
Original Source Link Visit Source Page on pmc.ncbi.nlm.nih.gov »